Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study
Author(s)
Chaves-Loureiro C1, Carriço F2, Brito U3, Belchior I4, Fernandes RA5, Sousa N6, Mendes A7, Loureiro C8, Pardal C9, Ribeiro L10, Reis G11, Pires N12, Teles C13, Plácido J14, Boaventura R15, Lima R16, Pardal M17, Marques A17, Martinho H17, Bernardo F17
1Pulmonology Department, Centro Hospitalar e Universitário de Coimbra; Centre of Pulmonology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, 2Centre of Integrated Responsibility of Sleep and non-Invasive Ventilation, Centro Hospitalar Universitário de São João, Porto, Portugal, 3Pulmonology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 4Pulmonology Department, Centro Hospitalar Universitário do Algarve, Portimão, Portugal, 5Allergology and Immunology Department, Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal, 6Allergology and Immunology Department, Centro Hospitalar de Leiria, Leiria, Portugal, 7Allergology and Immunology Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 8Allergology and Immunology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 9Pulmonology Department, Hospital Professor Doutor Fernando da Fonseca, Amadora, Portugal, 10Pulmonology Department, Centro Hospitalar Trás-os-Montes e Alto Douro, Vila Real, Portugal, 11Pulmonology Department, Hospital de Santarém, Santarém, Portugal, 12Pulmonology Department, Hospital Santa Maria Maior, Barcelos, Portugal, 13Pulmonology Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, 14Allergology and Immunology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 15Pulmonology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 16Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 17Medical Department, AstraZeneca, Barcarena, Portugal
Presentation Documents
OBJECTIVES: Severe asthma seriously contributes to the overall burden of asthma for patients across healthcare systems. In Portugal, direct costs related to asthma accounted for over 2% of the total healthcare expenditure in 2010. This analysis of the BETREAT study aims to evaluate the healthcare resource utilization (HRU) among severe eosinophilic asthma (SEA) patients in Portugal before and after starting treatment with benralizumab. This study is part of AstraZeneca’s global XALOC real-world evidence program.
METHODS: Observational, multicentric, retrospective study of adult SEA patients who started benralizumab treatment between July 2019 and October 2020. Data was collected from electronic medical records. Number of emergency room (ER) episodes, scheduled and unscheduled medical visits, and hospitalisations were assessed. A descriptive analysis was conducted for HRU at baseline (12-months prior to benralizumab first injection) and after 24-months follow-up.
RESULTS: 74 participants were included, 73.0% female, 74.3% aged < 65 years and 91.9% with at least one comorbidity reported. 32.4% of patients were previously biologic-treated. At baseline, patients had a mean (±SD) of 4.4±2.4 and 0.9±1.4 scheduled and unscheduled visits for asthma, respectively. During the follow-up period, most patients did not have ER episodes (77.0%) or hospitalisations (87.8%) and annual rate of ER episodes decreased from 1.5 at baseline to 0.2 episodes per year at 24-months. At baseline the mean (±SD) number of exacerbations that led to ER episodes and hospitalisations was 1.5±2.2 and 0.3±0.9, respectively, which decreased over the follow-up period to 0.8±1.2 and 0.2±0.6.
CONCLUSIONS: Benralizumab treatment led to a significant reduction in hospitalisations and ER episodes along with a decrease in the number of exacerbations. These results are consistent with pivotal clinical trials of the drug and suggest that better clinical control of asthma was associated with HRU reduction, which is a feasible target to decrease the burden of asthma across healthcare system.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HSD44
Disease
Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)